07:00 , Apr 29, 2013 |  BC Week In Review  |  Company News

Alitair Pharmaceuticals Inc. neurology, drug delivery news

Alitair said it would sell its abuse-deterrence technology patent at a sealed bid sale on May 24. The patent covers the use of ion-exchange resins (IER) in immediate-release and extended-release solid oral dosage forms, including...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Company News

Alitair Pharmaceuticals Inc., Cornerstone Therapeutics deal

Alitair granted Cornerstone a license to its IP covering solid oral dosage formulations, which the companies will use to collaborate on the development of one or more compounds to treat cough and cold. The license...